Diazepam AbZ

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diazepam AbZ

Property Description
Active Ingredient Diazepam
Form Tablet (Oral Dosage Form)
Pharmacological Class Benzodiazepine Derivative
General Purpose Relieves emotional tension and muscle stiffness
Origin Synthetic

Diazepam AbZ: A Definition and Type Classification

Diazepam AbZ is a synthetic, prescription-only psychotropic agent that belongs to the benzodiazepine derivative class of medicines. The medication's identity is defined by its active component, Diazepam, which is chemically and functionally classified as a central nervous system depressant. Its status as a prescription-only medicine confirms its classification as a potent agent requiring professional oversight. Diazepam AbZ is a product marketed by AbZ Pharma, a manufacturer primarily focused on generic medicines.

Composition and Presentation of Diazepam

The medicine is formulated as a single-ingredient oral dosage form, with Diazepam as its sole active pharmaceutical ingredient, presented as a tablet. Diazepam AbZ utilizes the well-characterized synthetic compound Diazepam within its tablet matrix. The choice of the tablet form distinguishes it for routine, scheduled administration, unlike liquid or injectable forms that are generally reserved for acute care settings. The established efficacy and safety of the compound are clinically recognized for managing conditions stemming from central nervous system over-activity.

General Purpose: Why is Diazepam Used?

The primary purpose of Diazepam is to provide relief from nervous system over-activity by inducing comprehensive calming and stabilizing effects. This action, characteristic of a powerful central nervous system depressant, grants the drug a multi-faceted profile, including anxiolytic (anti-anxiety), sedative, and muscle relaxant properties. Consequently, the medicine is generally utilized to address conditions such as severe emotional tension and unwanted muscle stiffness, reflecting its fundamental capacity to modulate excessive neuronal excitability.

Regulatory References

  1. Diazepam (Oral) - LiverTox - NCBI Bookshelf - NIH
  2. Diazepam: MedlinePlus Drug Information

What side effects are possible with Diazepam AbZ?

Possible Side Effects and Safety Information

The safety profile of Diazepam AbZ is primarily defined by the central nervous system (CNS) effects of its active ingredient, Diazepam, as documented in regulatory sources.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized by frequency, reflecting official regulatory data:

  • Common: Adverse reactions that may affect up to 1 in 10 people include drowsiness, fatigue, sedation, ataxia (lack of coordination), and muscle weakness. These effects are often most noticeable at the start of treatment and may lessen with continued use.
  • Uncommon / Rare: Less frequent effects involve the nervous system (e.g., confusion, dizziness, tremor, headache), gastrointestinal tract (nausea, constipation), and the cardiovascular system (hypotension).

Serious Adverse Reactions and Safety Concerns

The official labeling highlights several serious adverse reactions, which, while rare, are critical safety considerations:

  • Paradoxical Reactions: Reactions such as excitation, agitation, hallucinations, and psychoses are documented and are counter-intuitive to the drug's intended calming effect.
  • Respiratory Depression: This is a documented risk, particularly when higher doses are used or when the medicine is combined with other CNS depressants.
  • Dependence and Amnesia: Use is associated with a risk of developing physical and psychological dependence with prolonged exposure. The risk of anterograde amnesia (memory impairment for events after use) is also officially documented.

Population-Specific Safety Statements

Specific safety considerations are noted for certain patient groups:

  • Older Adults: The risk of sedation and ataxia is increased, contributing to a heightened risk of falls.
  • Contraindications: The medicine is officially contraindicated in individuals with severe respiratory insufficiency, sleep apnea syndrome, myasthenia gravis, and severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Diazepam defines overdose primarily by the degree of Central Nervous System (CNS) depression, with symptoms representing an exaggerated extension of the drug’s intended pharmacological activity.

Documented Manifestations and Severe Outcomes

Overdose Presentation Severe or Life-Threatening Outcomes
Common: Somnolence, confusion, diminished reflexes, lethargy, muscle weakness, impaired coordination, and hypotension. Potential: Coma, respiratory depression, cardiovascular collapse, and, rarely, death.

When to Seek Immediate Medical Attention

Regulatory guidance mandates seeking immediate medical attention or contacting emergency services for any suspected overdose. Urgent medical care is specifically required if symptoms escalate to involve:

  • Profound sleepiness or extreme lethargy.
  • Slow, shallow, or troubled breathing (respiratory depression).
  • Loss of consciousness or coma.

Risk and Management Considerations

Severe or fatal outcomes are significantly increased when Diazepam is co-ingested with other CNS depressants, notably alcohol or opioids. The official label specifies that elderly or debilitated patients and those with pre-existing hepatic or respiratory impairment face an increased risk for severe toxicity. Management involves general symptomatic and supportive care, including continuous monitoring of respiration, pulse, and blood pressure. A specific antagonist, Flumazenil, is available but is reserved for highly specific clinical circumstances as outlined in official prescribing information.

Therapeutic Uses of Diazepam AbZ

What Diazepam AbZ Treats: Main Uses and Benefits

The primary therapeutic role of Diazepam AbZ is to provide symptomatic relief across conditions marked by nervous system over-activity, offering supportive calming and stabilizing relief. The medication is commonly used across therapeutic domains involving heightened tension and physiological stress.


The medicine is used for managing symptoms associated with several clinical areas, including anxiety disorders, skeletal muscle spasms, acute alcohol withdrawal syndrome, and as an adjunct in certain convulsive disorders. It helps address symptom clusters that may become intense or disruptive, such as debilitating worry, physical agitation, and involuntary muscle hypertonia.

“It is commonly used when short-term symptomatic assistance is needed for tension or acute episodes that create noticeable functional strain.”

Diazepam AbZ generally assists with managing these distressing manifestations. It provides support that helps ease the overall symptom burden and assists with maintaining functional stability, contributing to improved comfort during periods of heightened symptoms. This action is relevant in contexts involving heightened systemic burden, such as pre-procedure relaxation or stabilization during acute withdrawal.

Quick Fact: Relevant for Severe Tension and Muscle Spasms

Eligibility and Restrictions for Use

Who Can and Cannot Use Diazepam AbZ?

Eligibility for using Diazepam AbZ is strictly defined by regulatory authorities based on pre-existing conditions and patient demographics, distinguishing between contraindicated, restricted, and permitted populations. This information is derived directly from official prescribing documents.


Absolute Contraindications

Use is formally contraindicated in patients with specific severe conditions due to the risk of exacerbation or serious adverse effects. These include myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, sleep apnoea syndrome, and acute narrow-angle glaucoma.

Age and Population Restrictions

  • Pediatric Use: The medicine is contraindicated in patients under six months of age because safety and efficacy have not been established. Use in children 6 months and older requires careful assessment.
  • Older Adults: Use in geriatric and debilitated patients requires a lower initial dose than the standard adult dose, and caution is necessary due to increased sensitivity and risk of accumulation.

Condition- and Status-Based Limitations

  • Psychological Status: The drug is not recommended as monotherapy for patients with depression or psychotic illness.
  • Reproductive Status: Use during pregnancy and lactation is not recommended due to potential risks to the fetus and infant. Women who are planning a pregnancy should also not use this medicine.

What should I know about interactions with other medicines?

Diazepam AbZ Interactions with other medicines and products

Interacting Substances and Restrictions

The interaction profile of Diazepam is governed by its metabolism and its central nervous system (CNS) effects. Regulatory authorities classify several combinations with significant constraints.

Classification Official Regulatory Information
Do Not Combine (High Risk) Alcohol (Ethanol): Should not be used together due to enhanced sedative and CNS inhibition effects. Opioids: Co-administration carries a severe risk of profound sedation, respiratory depression, coma, and death; prescribing is typically reserved for inadequate alternative treatment options (FDA Boxed Warning).
Avoid Combination Rifampicin: Co-administration should be avoided as this enzyme inducer increases the clearance of Diazepam, significantly decreasing its concentration and therapeutic effect.

Pharmacokinetic and Pharmacodynamic Effects

  • CYP Enzyme Inhibitors (e.g., Cimetidine, Fluoxetine, Omeprazole, Ketoconazole) reduce the elimination of Diazepam by inhibiting the CYP3A4 and CYP2C19 liver enzymes, leading to increased and prolonged plasma levels.
  • Other CNS Depressants (e.g., Antipsychotics, Sedatives, Anticonvulsants, Sedating Antihistamines) enhance the CNS depressant effects, which may result in severe sedation and cardiovascular or respiratory depression.
  • Sodium Valproate is documented to increase Diazepam's serum levels through displacement from protein-binding sites.
  • Grapefruit Juice and certain herbal products (e.g., Valerian, Passionflower) may also increase Diazepam levels or enhance its sedative effects.

Population-Specific Caution

Official labeling advises that particular attention must be paid to the potential for drug interactions in elderly patients, who are at an increased risk of accumulation and enhanced effects.

Mechanism of Action

Enhancing GABAergic Inhibition

The action of Diazepam is based entirely on enhancing the inhibitory signaling system within the Central Nervous System (CNS). It functions as a Positive Allosteric Modulator (PAM) by binding to a specific site on the GABA A receptor complex, which is a ligand-gated chloride ( Cl^-) ion channel. Diazepam requires the presence of the natural inhibitory neurotransmitter GABA to be effective. This interaction significantly increases the frequency of the channel's opening.

Molecular Cascade and Physiological Modulation

This molecular interaction enhances the influx of negative Cl^- ions into nerve cells, leading to neuronal hyperpolarization and a reduction in neuronal signal propagation. The resulting hyperpolarization raises the firing threshold of neurons across the brain, leading to a systemic reduction in neuronal depolarization potential—a central dampening effect. Diazepam preferentially engages GABA A receptors containing the alpha2 and alpha3 subunits, which are highly relevant in the motor interneurons of the spinal cord. This targeted pathway adjustment causes a direct decrease in motor neuron firing, resulting in the physiological outcome of decreased muscle tone.

Dosage and Administration Information

Official Administration Guidelines for Diazepam

The correct use of Diazepam is strictly defined by guidelines concerning the route, dosage, frequency, and duration of therapy. While Diazepam AbZ is an oral tablet, the drug is also available in other formulations for intravenous (IV), intramuscular (IM), rectal, and intranasal administration.


Dosing and Administration Schedules

The following oral dosing regimens are typically established for this medication:

Indication Focus Adult Dose Range Frequency Duration Pattern
Anxiety 2 mg to 10 mg per dose 2 to 4 times daily Short-term only
Skeletal Muscle Spasm 2 mg to 10 mg per dose 3 to 4 times daily Short-term only
Acute Alcohol Withdrawal 10 mg (initial dose) 3 to 4 times during first 24 hours Reduced to 5 mg, 3 –4 times daily as needed (PRN)

Special Administration Instructions

  • Duration of Use: Treatment duration should be as short as possible and, in general, must not last longer than 8 to 12 weeks, including the necessary tapering-off process. A patient re-evaluation is required after no more than 4 weeks.
  • Food Relationship: Taking the oral tablet with a moderate-fat meal delays and decreases the medicine's absorption, resulting in a lower peak concentration.
  • Population Adjustments: For older adults and debilitated patients, the initial oral dose must be reduced (typically 2 mg to 2.5 mg, 1 to 2 times daily) to minimize the risk of accumulation. Dose reduction is also mandatory for patients with hepatic impairment.
  • Discontinuation: To reduce the risk of withdrawal reactions, treatment must always be tapered off gradually; abrupt cessation is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diazepam AbZ

This section provides an overview of the types of official research that has been conducted on Diazepam and what the existing evidence base indicates, consistent with information reviewed by regulatory bodies. It is a description of research only and is not medical advice or treatment guidance.


Evidence for Use in Managing Severe Anxiety Symptoms

The foundation of the evidence for use in conditions characterized by fluctuating or episodic manifestations includes short- to intermediate-term Randomized Controlled Trials (RCTs). Research examined the medication’s role in contexts associated with severe anxiety by measuring outcomes related to systemic or functional imbalance using standardized clinical scales. Findings describe patterns observed in studies where trials reported measured changes in anxiety scale scores over observation periods lasting approximately four to six weeks. What remains unclear is the long-term study of symptom patterns; long-term effects are not fully established in controlled clinical research for continuous use.


Research Foundation for Skeletal Muscle Spasm and Spasticity

Research has explored changes related to muscle stiffness (hypertonia) in relation to the medication in conditions where symptoms may vary in intensity. The available studies include RCTs and specialized clinical trials. Research monitored outcomes related to physical discomfort, including measures of muscle stiffness and patient-reported outcomes. Acute trials reported measurements of a change in muscle tension compared to baseline over short intervention durations. A key research limitation is that evidence quality varies across studies for acute muscle conditions, and there is limited information for long-term outcomes regarding daily functioning.


What is Still Uncertain About the Research for Diazepam AbZ

This overview highlights that while there is an established body of evidence for the drug's short-term role, several research gaps remain concerning extended use. There is limited information for long-term outcomes for many continuous uses, as studies conducted during periods of increased symptom activity have generally limited follow-up durations. Comparative evidence is lacking in some areas against the full spectrum of newer treatment options. The evidence quality varies across studies, and while some findings describe group patterns, they do not provide context or individual predictions about personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Diazepam AbZ (FAQ)


Q: How quickly is Diazepam AbZ described as starting to work?

According to the official product information, after the oral tablet is taken, the active substance is quickly absorbed. Peak concentrations of the medicine in the blood are typically reached within 1 to 1.5 hours, although this can range from 15 minutes up to 2.5 hours depending on the individual.


Q: How long does the described effect of Diazepam AbZ usually last?

Official product information suggests that the immediate effects may be perceived for up to 12 hours after a single dose. However, regulatory documents describe the medicine as having a long elimination half-life, which means the substance remains in the body for an extended period.


Q: Are there common misunderstandings about the safety of Diazepam AbZ?

Regulatory warnings primarily address the documented safety risks, including the potential for abuse, misuse, and addiction, particularly with long-term use. There are also severe risks detailed in official labeling regarding its combination with other central nervous system depressants, especially alcohol and opioid medications.


Q: Can Diazepam AbZ be used for short periods of time?

Official guidelines recommend that treatment duration be kept as short as possible due to the risk of dependence. In general, the total duration of treatment, including the necessary dose reduction period, should not exceed 8 to 12 weeks.


Q: Is Diazepam AbZ considered a medicine for long-term use?

Official guidelines restrict the continuous use of the medicine, stating that treatment must be limited to 8 to 12 weeks. This caution is reinforced by research overviews indicating that the long-term effects of continuous use are not fully established in controlled clinical studies.


Q: Can the described effect of Diazepam AbZ vary based on a person’s weight or age?

Yes, regulatory documents describe that the medicine’s elimination half-life increases with age. As a result, dosage adjustments are often necessary for older adults and debilitated patients to minimize the risk of the drug accumulating in the body.


Q: What types of activities might be affected by using Diazepam AbZ?

The medicine is a central nervous system depressant and can slow down brain activity, interfering with judgment, thinking, and motor skills. Official warnings describe that patients should refrain from activities requiring complete alertness, such as driving or operating machinery.


Q: Are there any specific lifestyle items, like herbal supplements, that might interact with Diazepam AbZ?

Regulatory warnings mention potential interactions with Grapefruit Juice and certain herbal products such as Valerian and Passionflower. Official documents indicate that these substances may affect the medicine’s concentration in the body or enhance its calming effects.


Q: Are there any documented research findings on Diazepam AbZ that are often cited?

Research reviewed by regulatory bodies includes short- to intermediate-term trials that have reported measured changes in standardized anxiety scale scores. Other cited research themes involve monitoring outcomes related to a change in muscle tension and exploring the drug's effect on brain function.


Q: Is there a described period of time when Diazepam AbZ should not be used?

The medicine is formally contraindicated in patients with severe pre-existing conditions. These conditions include myasthenia gravis (a muscle weakness condition), severe respiratory insufficiency, severe hepatic insufficiency (liver problems), sleep apnoea syndrome, and acute narrow-angle glaucoma.


Q: Is it normal to feel a bit unsteady when starting Diazepam AbZ?

Lack of coordination, known as ataxia, is listed as a common adverse reaction in official safety documents. These common effects, which also include drowsiness and fatigue, are often most noticeable when treatment begins and may lessen with continued use.


Q: Is there any research on the effects of long-term use of Diazepam AbZ?

While evidence is established for short-term use, regulatory overviews indicate that the long-term effects of continuous use are not fully established in controlled clinical research. Most studies conducted during periods of increased symptom activity have generally limited follow-up durations.


Q: What is the connection between Diazepam AbZ and sleep problems?

The medicine is sometimes indicated as a sedative agent for the short-term management of insomnia when associated with anxiety. Conversely, it is formally contraindicated (should not be used) in patients diagnosed with sleep apnea syndrome.


Q: What is the connection between Diazepam AbZ and muscle weakness/control?

The medicine's mechanism of action directly decreases motor neuron firing, which results in decreased muscle tone. Accordingly, muscle weakness is listed as a common adverse effect, and the medicine is formally contraindicated in patients with myasthenia gravis.


Q: Is Diazepam AbZ described as having a risk of dependence?

Official labeling documents clearly state that the use of this medicine is associated with a risk of developing both physical and psychological dependence with prolonged exposure. For this reason, regulatory guidelines generally recommend limiting treatment to a short duration.


Q: Why do official guidelines emphasize caution when using Diazepam AbZ?

Caution is noted in official guidelines due to the documented risks of developing physical and psychological dependence and the potential for serious adverse reactions. This includes the risk of respiratory depression and the severe risks associated with its co-administration of opioids and alcohol.


Q: Does Diazepam AbZ affect driving according to official patient information?

Official patient information describes that the medicine can interfere with a person's judgment and motor skills. Patients should refrain from driving a car or operating machinery until they are certain of how the medicine affects them and whether they feel fully alert.


Q: What does 'tolerance' mean in the context of taking Diazepam AbZ?

Tolerance, in this context, is described as the effect where the body may require progressively higher doses over time to achieve the same therapeutic effect that was felt initially. This effect is associated with long-term use.


Q: Can the described side effects of Diazepam AbZ change over time?

Yes. According to frequency-classified adverse reactions, common effects like drowsiness and fatigue are often most noticeable when treatment begins. These symptoms may lessen in intensity with the continued use of the medicine.


Q: What is the role of Diazepam AbZ in managing seizure disorders?

The medicine is officially indicated for the treatment of certain seizure disorders. Its various formulations, including non-oral ones, are used in managing acute convulsive episodes, such as a severe, prolonged seizure known as status epilepticus.


Q: Is it true that Diazepam AbZ is sometimes used before medical procedures?

Yes. Regulatory documents confirm the medicine is officially used as a premedication and a sedative. This use is intended to provide calming and relaxation effects before certain surgical, endoscopic, and other medical procedures.


Q: Are there certain groups of people who are described as needing closer monitoring while on Diazepam AbZ?

Older adults are noted in official labeling as needing particular attention and monitoring due to an increased risk of accumulation and enhanced effects. Additionally, patients at elevated risk for abuse, misuse, and addiction necessitate counseling and close monitoring.


Q: Are there alternatives to Diazepam AbZ described in official literature for the same conditions?

Regulatory literature and therapeutic reviews may mention that alternative treatment options exist, depending on the condition being treated. For anxiety, these may include different classes of medication such as SSRIs or SNRIs, and for seizure disorders, various anticonvulsants may be used.


Q: What is the half-life of Diazepam as described in regulatory documents?

The elimination half-life of the active substance, Diazepam, is approximately 48 hours, with a range documented from 20 to 100 hours. Its main active metabolite, desmethyldiazepam, also has a very long half-life, which can be up to 200 hours.


Q: Why are official prescribing limits often short for Diazepam AbZ?

Official prescribing limits are short, generally not exceeding 8 to 12 weeks. The short duration generally recommended is associated with minimizing the risks of developing physical and psychological dependence and tolerance with prolonged use.


Q: What kind of mental/mood changes are described as possible with Diazepam AbZ use?

Possible changes include nervous system effects like confusion, dizziness, and headache. Serious, though rare, paradoxical reactions are also documented, which are the opposite of the intended calming effect, such as excitation, agitation, hallucinations, and psychoses.

How should Diazepam AbZ be stored and disposed of?

The official regulatory profile for Diazepam AbZ tablets specifies strict conditions necessary for product stability and safety.

Required Storage Conditions

Diazepam tablets must be stored at a temperature at or below 25°C (77°F). Storage must occur within the original container/package, and the blister should be kept in the outer carton to protect from moisture.

Child Safety and Disposal

It is a mandatory requirement to keep this medicine out of the sight and reach of children.

For disposal, regulatory documents state that unused or expired medicine must be returned to the pharmacist. The medicine must not be thrown away via wastewater or household waste to prevent environmental contamination and misuse, aligning with standard pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diazepam AbZ found in:

A-Z Index: